Humanigen’s stock tumbles 67% after sharing new clinical data for its COVID-19 treatment

Shares of Humanigen Inc.
HGEN,
-80.10%
plunged 67.9% in premarket trading on Wednesday, the day after the company said a National Institutes of Health clinical trial testing lenzilumab and Gilead Sciences Inc.’s
GILD,
+0.32%
Veklury in hospitalized COVID-19 patients did not produce the same benefit as it did in previous studies. Humanigen’s stock is down 19.6% this year, while the S&P 500
SPX,
-0.29%
has declined 19.9%.